Is Onfi affected by genetics?

Yes — the active ingredient is metabolized by a gene known to vary between individuals.

Relevant genes: CYP2C19

Considering GeneSight for Onfi?

Gene2Rx covers this medication using the same CPIC and FDA guidelines GeneSight uses, costs $5-$49 instead of several hundred, and works with your existing 23andMe data.

See the comparison →

Onfi is affected by pharmacogenetics through the CYP2C19 gene. Your genotype for this gene can change how your body processes Onfi, which can affect both how well it works and how well you tolerate it. The strongest evidence level on this page is Strong, based on CPIC or FDA guidelines.

What's in Onfi

clobazam affected by CYP2C19

Affected by CYP2C19 · FDA · Strong evidence

Read the full clobazam genetics guide →

Clobazam phenotype recommendations

Published guidance from FDA on how clobazam should be dosed or substituted based on your CYP2C19 phenotype.

Phenotype	What it means	Recommendation	Evidence
Ultrarapid Metabolizer CYP2C19	Your body processes clobazam faster than normal. The standard dose should work as expected.	FDA Initiate therapy with recommended starting dose.	—
Rapid Metabolizer CYP2C19	Your body processes clobazam slightly faster than normal. The standard dose should work as expected.	FDA Initiate therapy with recommended starting dose.	—
Normal Metabolizer CYP2C19	Your body processes clobazam at a normal rate. The standard dose should work as expected.	FDA Initiate therapy with recommended starting dose.	—
Intermediate Metabolizer CYP2C19	Your body breaks down clobazam more slowly than normal, causing higher levels of the drug's active form to build up. A lower dose may be needed to reduce the risk of side effects.	FDA Adjust dose per FDA labeling due to higher active metabolite concentrations and increased adverse reaction risk.	Moderate
Poor Metabolizer CYP2C19	Your body breaks down clobazam much more slowly than normal, causing the drug's active form to build up to high levels. A significantly lower dose is recommended to avoid serious side effects.	FDA Reduce dose significantly per FDA labeling due to substantially higher active metabolite concentrations and adverse reaction risk.	Strong
Indeterminate CYP2C19	The impact of your genotype on response to this drug is unknown	FDA Initiate therapy with recommended starting dose.	—
Not available CYP2C19	The impact of your genotype on response to this drug is unknown	FDA Initiate therapy with recommended starting dose.	—

Source: FDA

The gene behind the guidance

CYP2C19 Cytochrome P450 2C19

CYP2C19 handles several SSRIs (citalopram, escitalopram, sertraline), proton pump inhibitors (omeprazole, esomeprazole), and the blood thinner clopidogrel. About 2 to 5 percent of people of European descent and 15 to 20 percent of people of East Asian descent are poor metabolizers. Another 30 percent carry a rapid-metabolizer variant.

Rapid metabolizers clear affected drugs before they reach therapeutic levels. Poor metabolizers accumulate the drug and feel stronger effects.

See all drugs affected by CYP2C19 →

Browse the full drug-class: Anticonvulsants.

Related medications

Find out how your genetics affect Onfi

This page describes the general pharmacogenetics. A Gene2Rx report analyzes your own DNA to tell you which metabolizer group you fall into, across every medication.

Get your report Look up another medication

Informational only — not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.